2024
‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder
Myers A, Tan W, de Groot J, Westney O, Kamat A. ‘Case of the Month’ from The University of Texas MD Anderson Cancer Center, Houston, Texas, USA: ependymoma of the urinary bladder. BJU International 2024, 134: 45-47. PMID: 38379218, DOI: 10.1111/bju.16302.Peer-Reviewed Original Research
2023
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBCG VaccineCystectomyHumansNon-Muscle Invasive Bladder NeoplasmsUrinary BladderUrinary Bladder NeoplasmsUrologyConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalImpact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisSequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalBCG VaccineDocetaxelGemcitabineHumansNon-Muscle Invasive Bladder NeoplasmsRetrospective StudiesUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer groupClinical trial design for non-muscle-invasive bladder cancer
Tan W, Hall E, Kamat A, Kelly J. Clinical trial design for non-muscle-invasive bladder cancer. Nature Reviews Urology 2023, 20: 575-576. PMID: 37328547, DOI: 10.1038/s41585-023-00789-0.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCystectomyHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsBacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal?
Tan W, Grajales V, Bree K, Li R, Nogueras‐Gonzalez G, Navai N, Dinney C, Kamat A. Bacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal? BJU International 2023, 132: 384-386. PMID: 37246493, DOI: 10.1111/bju.16087.Peer-Reviewed Original ResearchReply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4
Heer R, Tan W, Gravestock P, Vadiveloo T, Lewis R, Penegar S, Vale L, MacLennan G, Hall E, Team P. Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4. European Urology 2023, 85: 309-312. PMID: 37330372, DOI: 10.1016/j.eururo.2023.05.040.Peer-Reviewed Original ResearchMeSH KeywordsHumansTransurethral Resection of BladderUrinary Bladder NeoplasmsUrologic Surgical ProceduresRobot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials
Khetrapal P, Wong J, Tan W, Rupasinghe T, Tan W, Williams S, Boorjian S, Wijburg C, Parekh D, Wiklund P, Vasdev N, Khan M, Guru K, Catto J, Kelly J. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. European Urology 2023, 84: 393-405. PMID: 37169638, DOI: 10.1016/j.eururo.2023.04.004.Peer-Reviewed Original ResearchMeSH KeywordsCystectomyHumansPostoperative ComplicationsQuality of LifeRandomized Controlled Trials as TopicRobotic Surgical ProceduresRoboticsTreatment OutcomeUrinary Bladder NeoplasmsConceptsRobot-assisted radical cystectomyOpen radical cystectomyRadical cystectomyBlood lossThromboembolic eventsAssociated with better physical functionBladder cancerPositive surgical margin rateAssociated with more blood lossRisk of thromboembolic eventsHealth-related QoLQuality of life outcomesProgression-free survivalSurgical margin rateLymph node yieldRobot-assisted approachShorter operative timeShorter hospital lengthQuality of lifeRandomized controlled trialsSystematic literature searchPhysical functionWeb of ScienceNode yieldOverall survivalEvolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellHumansImmune Checkpoint InhibitorsImmunoconjugatesImmunotherapyUrinary Bladder NeoplasmsConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Mustard C, Kelly J, team H. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e48-e49. PMID: 36456403, DOI: 10.1016/j.eururo.2022.11.006.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalHumansMitomycinNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsReply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Kelly J, team H. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e29-e30. PMID: 36272948, DOI: 10.1016/j.eururo.2022.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalHumansMitomycinNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAdjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly J. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology 2022, 83: 497-504. PMID: 35999119, DOI: 10.1016/j.eururo.2022.08.003.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAntibiotics, AntineoplasticChemotherapy, AdjuvantHumansMitomycinNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerDisease-free survivalAdverse eventsBladder cancerMitomycin CChemotherapy instillationOpen-labelControl armAdjuvant intravesical chemotherapyProgression-free survivalPhase 2 randomised controlled trialIntention-to-treat analysisLow gradePer-protocol analysisChemohyperthermia groupIntravesical chemotherapyUrinary cytologyHeated chemotherapyOverall survivalWeekly instillationsTumor resectionPrimary endpointRandomised controlled trialsChemohyperthermiaIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineConsensusHumansUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidanceA gender-related dichotomy in bladder cancer.
Cimadamore A, Teoh J, DI Trapani E, Krajewski W, Tan W, Mori K, Del Giudice F, Carrion D, Moschini M. A gender-related dichotomy in bladder cancer. Minerva Urologica E Nefrologica 2022, 74: 376-378. PMID: 35607787, DOI: 10.23736/s2724-6051.22.04954-0.Peer-Reviewed Original Research
2021
Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion
Abozaid M, Tan W, Khetrapal P, Baker H, Duncan J, Sridhar A, Briggs T, Selim M, Abdallah M, Elmahdy A, Elserafy F, Kelly J. Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion. BJU International 2021, 129: 72-79. PMID: 34092021, DOI: 10.1111/bju.15505.Peer-Reviewed Original ResearchConceptsGlobal HRQoL scoreHealth-related quality of lifeRobot-assisted radical cystectomyEORTC QLQ-C30HRQoL scoresQuality of lifeSexual functionRadical cystectomyUrinary diversionIleal conduitIC patientsRecovery of health-related quality of lifeFunction scoresClavien-Dindo complicationsHealth-related qualityPhysical function scoresRehabilitation of sexual functionIntracorporeal urinary diversionLongitudinal analysisSexual function scoresEuropean Organisation for ResearchMonths follow-upEORTC QLQ-BLM30Higher sexual function scoresReturn to baselineIs delay to radical cystectomy following BCG failure oncologically safe?
Tan W, Kelly J. Is delay to radical cystectomy following BCG failure oncologically safe? Nature Reviews Urology 2021, 18: 323-324. PMID: 33772157, DOI: 10.1038/s41585-021-00457-1.Peer-Reviewed Original Research
2020
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Woldu S, Ng C, Loo R, Slezak J, Jacobsen S, Tan W, Kelly J, Lough T, Darling D, van Kessel K, de Jong J, van Criekinge W, Shariat S, Hiar A, Brown S, Boorjian S, Barocas D, Svatek R, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. Journal Of Urology 2020, 205: 1387-1392. PMID: 33356483, DOI: 10.1097/ju.0000000000001550.Peer-Reviewed Original ResearchConceptsIncidence of bladder cancerBladder cancerHigh-risk groupRisk groupsRisk strataCancer incidenceDegree of hematuriaHigh-risk patientsRisk stratification systemAmerican Urological AssociationEvaluation of patientsMultinational cohort studyRisk-stratified approachBladder cancer incidenceHematuria patientsClinically meaningful categoriesGross hematuriaUrologic evaluationIntermediate riskProspective registryRisk patientsContemporary patientsSmoking historyUrological AssociationHematuriaMorbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group
Mortezavi A, Crippa A, Edeling S, Pokupic S, Dell’Oglio P, Montorsi F, D'Hondt F, Mottrie A, Decaestecker K, Wijburg C, Collins J, Kelly J, Tan W, Sridhar A, John H, Canda A, Schwentner C, Rönmark E, Wiklund P, Hosseini A. Morbidity and mortality after robot‐assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. BJU International 2020, 127: 585-595. PMID: 33058469, PMCID: PMC8246851, DOI: 10.1111/bju.15274.Peer-Reviewed Original ResearchConceptsPatients aged <Intracorporeal urinary diversionCancer-specific mortalityOther-cause mortalityPostoperative complicationsRadical cystectomyMortality rateUrinary diversionBladder cancerOutcomes of patients aged <Predictor of high-grade complicationsHigh-grade complication rateOther-cause mortality ratesRobot-assisted radical cystectomyMultivariate logistic regression analysisClavien-Dindo gradeLaparoscopic radical cystectomyHigh-grade complicationsPostoperative mortality rateMinimally invasive approachTreatment-related risksLogistic regression analysisOCM ratesPostoperative variablesComplication rateDelayed blood transfusion is associated with mortality following radical cystectomy
Tan W, Wang Y, Trinh Q, Preston M, Kelly J, Hrouda D, Kibel A, Krasnow R, Liu J, Chung B, Chang S, Mossanen M. Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal Of Urology 2020, 54: 290-296. PMID: 32538224, DOI: 10.1080/21681805.2020.1777195.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood TransfusionCohort StudiesCystectomyFemaleHumansMaleMiddle AgedRetrospective StudiesTime FactorsTime-to-TreatmentUrinary Bladder NeoplasmsConceptsDelayed blood transfusionEarly blood transfusionBlood transfusionRadical cystectomyBladder cancer treated with radical cystectomyPatients treated with radical cystectomyAssociated with 90-day mortalityIncreased 90-day mortalityTime of blood transfusionPrimary end pointRetrospective cohort studyMultivariate logistic regressionAssociated with mortalityDelayed transfusionMedian ageClinical deteriorationCystectomyHigher CCIOlder patientsTransfusionCohort studyEnd pointsPatient mortalityPatientsIndex admissionEditorial Comment.
Tan W, Kelly J. Editorial Comment. Journal Of Urology 2020, 204: 56-57. PMID: 32282283, DOI: 10.1097/ju.0000000000000786.02.Peer-Reviewed Original Research